2021

Read Dal Negro R W, Turco P, Povero M. The contribution of patients’ lung function to the inspiratory airflow rate achievable through a DPIs’ simulator reproducing different intrinsic resistance rates. Multidis Res Med 2021 Apr.15;16
Read Dal Negro RW, Turco P, Povero M. Assessing the Global Usability of Dry Powder Inhalers: Analysis of Six Devices Widely Used for Asthma. J Pulm Med Respir Res 2021, 7: 064
Read Carpagnano GE, Resta E, Povero M, Pelaia C, D’Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro MPF. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Sci Rep. 2021 Mar 9;11(1):5453
Read Ghetti G, D’Avella MC, Pradelli L. Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy. Clinicoecon Outcomes Res. 2021;13:121-133. Published 2021 Feb 10
Read Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organ J. 2021 Jan 27;14(2):100509